Literature DB >> 16113001

Analysis of recurrent mitral regurgitation after mitral valve repair.

Hong Ju Shin1, Yong Jik Lee, Suk Jung Choo, Hyun Song, Cheol Hyun Chung, Jae Won Lee.   

Abstract

Mitral valve repair was performed in 437 patients with mitral regurgitation from January 1994 to January 2002. The causes of mitral regurgitation were degenerative in 238 (54%), rheumatic in 134 (31%), and others in 65 (15%). The most frequently employed surgical techniques were ring annuloplasty in 417 (95%) cases, new chordae formation in 216 (50%), and quadrangular resection in 117 (27%). The mean follow-up was 29.04 +/- 22.81 months. There were 5 (1.2%) early and 5 (1.2%) late deaths. The reoperation rate was 1.6% with 41 (9%) cases of recurrent mitral regurgitation. Of these 22 were procedure-related: incomplete repair in 13, discordant new chordal length in 7, suture dehiscence and leaflet perforation in 1 case each. There were 19 cases of valve related failures: progression of rheumatic disease in 18 and subacute infective endocarditis in 1. Valve-related failure strongly correlated with progression of rheumatic disease. As initial operative success was the prime determinant of repair durability, intraoperative repair assessment with transesophageal echocardiography was essential.

Entities:  

Mesh:

Year:  2005        PMID: 16113001     DOI: 10.1177/021849230501300315

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  2 in total

1.  A case of infective endocarditis diagnosed by transesophageal but not transthoracic echocardiography.

Authors:  Hiroaki Mitsunari; Minoru Nomura
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

2.  Residual Mitral Regurgitation After Repair for Posterior Leaflet Prolapse-Importance of Preoperative Anterior Leaflet Tethering.

Authors:  Taichi Sakaguchi; Nobuyuki Kagiyama; Misako Toki; Arudo Hiraoka; Akihiro Hayashida; Toshinori Totsugawa; Kentaro Tamura; Genta Chikazawa; Hidenori Yoshitaka; Kiyoshi Yoshida
Journal:  J Am Heart Assoc       Date:  2018-06-01       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.